Abbott
Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.
A trio of medical device giants notched another win against Johnson & Johnson(NYSE:JNJ) after a Federal Circuit judge upheld a lower court’s ruling that invalidated stent patents held by J&J subsidiary Cordis Corp.
Abbott kicks off a Japanese trial for its “dissolving” vascular scaffold
Abbott OKs $3B share buyback, dividend
Abbott, Boston Scientific pay almost no taxes in Ireland despite billions in profits | Wall Street Beat
Is Valeant About To Make A Bold Bid For Bausch & Lomb?
Never let it be said that Valeant (NYSE: VRX) management is shy about doing deals. With a roster of past deals including Biovail, Cephalon, OraPharma, and Medicis, Valeant claims that better than 80% of its deals have attained the 20% internal return target it uses to evaluate potential transactions. If rumors out Friday prove true, Valeant is about to bag its biggest target yet in what would be a particularly bold move.
Abbott touts CE Mark for “world’s longest” coronary DES
Stentys enrolls 1st patient in U.S. stent trial
Stentys SA (EPA:STNT) hoping a new U.S. clinical trial will help it win pre-market approval for a self-apposing coronary stent.
The Princeton, N.J.- and Paris-based medical device company said it enrolled the 1st patient in its Apposition V trial, under an investigational device exemption from the U.S. watchdog agency.
Diabetes: Abbott’s glucose monitor software glitch gets FDA’s highest-risk recall
The FDA slapped its highest-risk label on Abbott’s (NYSE:ABT) blood glucose meter recall, deeming the software glitch potentially deadly for patients.
Abbott last month said that it had already issued a free software update to patch the problem, which may affect as many as 50,000 FreeStyle InsuLinx blood glucose meters on the market.
India slashes drug-eluting stent reimbursement by 62% | Wall Street Beat
The Indian government slashed reimbursement rates for drug-eluting stents by more than 61.5%, down to about $460 from roughly $1,200, aiming to give a boost to its domestic stents industry at the expense of the multinational players.
It’s the 2nd rate cut since October 2011, according to the Business Standard. India cut the rate of reimbursement for U.S.-made stents from 65,000 rupees (about $1,200) to 25,000 rupees (~$461), which is now the standard rate for stents regardless of origin, according to the newspaper.